From Nasdaq: 2025-06-25 22:47:00

Amgen stock (NASDAQ:AMGN) dropped 6% after mid-stage trial results for obesity drug MariTide showed the need for lower initial dosage to reduce side effects. Amgen plans Phase 3 trials with gradual dosage increase. Peak sales for MariTide could surpass $5 billion, making Amgen a promising investment at $270 per share.

Amgen’s valuation is on par with the S&P 500, with P/S ratio of 4.6, P/FCF ratio of 14.4, and P/E ratio of 26.4. Revenue growth has averaged 9.3% over the past 3 years, with recent quarterly revenue up 9.4%. Profitability metrics show moderate margins compared to peers, while the balance sheet appears somewhat weak.

Despite average profitability and weak financial stability, Amgen has shown resilience during market downturns, outperforming the S&P 500 in previous crashes. With strong growth and downturn resilience, Amgen remains a strong buy at $270 per share. Investors seeking lower volatility can consider the Trefis High Quality (HQ) portfolio for consistent outperformance.



Read more at Nasdaq: Buy, Sell, Or Hold Amgen Stock At $270?